Delivery Order SPE2DB25D2207-SPE2DB25FQRAA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $104,137.72 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen medication on August 14, 2025, with completion targeted for August 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant used to treat inflammatory skin conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $31,745.57 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen injectors on July 24, 2025, with completion targeted for July 25, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being performed at the contractor's facility in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat autoimmune and inflammatory conditions, reflecting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $28,876.66 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml in pen format. This firm fixed-price contract, awarded on May 12, 2025, represents a non-competitive delivery order under a larger indefinite delivery contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with a completion date of May 13, 2025. SKYRIZI is a biologic medication used...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,515.57 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML pen/milliliter on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $91,962.07 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen/ml pharmaceutical supplies. This firm fixed price delivery order, awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, was competitively awarded without set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant medication...
- The Defense Logistics Agency awarded a delivery order valued at $15,904.96 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors. This firm fixed price, non-competitive delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. SKYRIZI is a prescription biologic medication used to treat...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors on June 2, 2025, with completion expected by June 3, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. SKYRIZI is a biologic immunosuppressant used to...
- The Defense Logistics Agency (DLA) awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/milliliter pharmaceutical product on September 4, 2025, with completion expected by September 5, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $279,751.97 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 150 MG/ML in pen/milliliter formulation. This is a firm fixed price contract with no set-aside designation, executed as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract is set to be completed by September 9, 2025, with fulfillment occurring at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $52,711.33 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of SKYRIZI 150 mg/mL pen injections, with final delivery required by August 28, 2025. This competitively awarded contract utilizes firm fixed-price pricing and carries no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs across the Defense Health...
- SPE2DB25D2207Indefinite Delivery Contract
- SPE2DB25D2207-SPE2DB25FQRAADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $26,227.70 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/milliliter pharmaceutical product on June 2, 2025, with a completion date of June 3, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic medication used in the treatment of inflammatory skin conditions, reflecting the Defense Logistics Agency's broader pharmaceutical procurement responsibilities for military and federal healthcare systems. This delivery order represents a single transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply agreement extending through December 2026. As a primary pharmaceutical distributor for federal medical supply chains, AmerisourceBergen Drug Corp leverages this IDC to fulfill diverse medical supply requirements across therapeutic domains for military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities worldwide. The company's status as a prime contractor on this global pharmaceutical support vehicle demonstrates its capability to meet competitive federal procurement standards and support critical military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.2k | 6/2/25 |